Clene (CLNN) Financials: History & Chart

Clene Inc.(CLNN)

Biotechnology · Salt Lake City, UT

$3.97+0.06 (+1.53%)

Delayed quote: Oct 6, 2026, 12:18 PM EDT

About Clene Inc.

Clene Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to the discovery, advancement, and market introduction of pioneering therapeutic agents utilizing clean-surfaced nanotechnology (CSN). CNM-Au8 stands as its flagship compound, currently under evaluation across a diverse range of clinical studies. This includes a pivotal Phase 2/3 study intended for regulatory submission in individuals battling amyotrophic lateral sclerosis (ALS). The company has successfully concluded a Phase 2 proof-of-concept trial for those with early manifestations of ALS. Furthermore, two open-label, investigator-blinded Phase 2 trials assessing brain energy metabolism have been finished. An ongoing Phase 2 trial is investigating CNM-Au8's potential to mitigate visual pathway deficits stemming from chronic optic neuropathy, aiming for remyelination in stable relapsing Multiple Sclerosis patients. A Phase 2 clinical investigation targeting Parkinson's Disease patients is also slated for commencement. Beyond its leading candidate, Clene's pipeline extends to include CNM-AgZn17. This gel formulation, comprising silver and zinc ions, is in development to combat infectious diseases and hasten wound recovery. Additionally, CNM-ZnAg acts as a broad-spectrum antiviral and antibacterial compound, designed to address various infectious conditions like COVID-19, while also offering immune support for symptom alleviation. For oncology, CNM-PtAu7 is a gold-platinum CSN therapeutic agent currently in development. The company also distributes dietary supplements, featuring rMetx, a liquid supplement containing zinc-silver ions, and KHC46, an aqueous gold supplement with trace amounts of gold nanoparticles. Clene Inc. maintains its headquarters in Salt Lake City, Utah.

Salt Lake City, UT

78 employees

clene.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert Etherington

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	197K	90K	15K	77K	15K	27K	81K	91K	87K
Cost of Goods Sold	414K	36K	355K	23K	0.00	0.00	20K	18K	18K
Gross Profit	-217K	54K	-340K	54K	15K	27K	61K	73K	69K
Gross Profit Margin	-110.2%	60.0%	-2266.7%	70.1%	100.0%	100.0%	75.3%	80.2%	79.3%
Total Operating Expenses	20.08M	5.40M	1.72M	7.30M	5.66M	5.89M	4.14M	8.73M	7.88M
Research & Development	12.82M	3.47M	329K	5.50M	3.51M	3.51M	1.48M	5.57M	4.47M
Selling, General & Administrative	7.64M	1.93M	1.75M	1.81M	2.15M	2.19M	2.66M	2.70M	3.41M
Operating Income (EBIT)	-20.30M	-5.35M	-2.06M	-7.24M	-5.65M	-5.86M	-4.08M	-8.65M	-7.82M
Operating Margin	-10304.6%	-5941.1%	-13740.0%	-9407.8%	-37653.3%	-21718.5%	-5032.1%	-9511.0%	-8982.8%
Income Before Tax (EBT)	-39.52M	-13.42M	-8.09M	-9.23M	-8.78M	-7.42M	-751K	-13.55M	-7.99M
Interest Income	182K	55K	47K	40K	40K	62K	81K	110K	127K
Interest Expense	2.88M	695K	791K	746K	649K	679K	608K	516K	1.02M
Other Income/Expense	-19.22M	-8.08M	-6.03M	-1.98M	-3.13M	-1.55M	3.33M	-4.89M	-171K
Net Income	-39.52M	-13.42M	-8.09M	-9.23M	-8.78M	-7.42M	-751K	-13.55M	-7.99M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-20059.9%	-14915.6%	-53940.0%	-11981.8%	-58513.3%	-27477.8%	-927.2%	-14889.0%	-9179.3%
EBITDA	-18.87M	-4.99M	-1.71M	-6.88M	-5.28M	-5.50M	-3.67M	-8.25M	-7.41M
EBITDA Margin	-9577.2%	-5548.9%	-11373.3%	-8940.3%	-35220.0%	-20363.0%	-4533.3%	-9065.9%	-8516.1%
Depreciation & Amortization	1.43M	353K	355K	360K	365K	366K	404K	405K	406K
EPS Basic	-3.55	-1.08	-0.69	-0.93	-0.85	-0.78	-0.09	-1.95	-1.22
EPS Diluted	-3.55	-1.08	-0.69	-0.93	-0.85	-0.78	-0.09	-1.95	-1.22
Weighted Average Basic Shares	12.38M	12.38M	11.64M	9.86M	10.28M	9.52M	8.82M	6.95M	6.55M
Weighted Average Diluted Shares	12.38M	12.38M	11.64M	9.86M	10.28M	9.52M	8.82M	6.95M	6.56M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	200K	342K	654K	473K	723K	206K	0.00	0.00
Cost of Goods Sold	43K	70K	121K	26K	289K	65K	900K	0.00
Gross Profit	157K	272K	533K	447K	434K	141K	-900K	0.00
Gross Profit Margin	78.5%	79.5%	81.5%	94.5%	60.0%	68.4%	N/A	N/A
Total Operating Expenses	23.24M	33.37M	41.07M	48.86M	50.41M	20.36M	15.43M	324K
Research & Development	14.01M	20.06M	26.66M	31.92M	28.42M	15.20M	8.76M	6.64M
Selling, General & Administrative	9.23M	13.31M	14.42M	16.16M	18.81M	3.26M	6.67M	324K
Operating Income (EBIT)	-23.08M	-33.09M	-40.54M	-48.41M	-49.98M	-20.21M	-16.33M	-324K
Operating Margin	-11541.5%	-9676.3%	-6198.8%	-10234.5%	-6912.6%	-9812.6%	N/A	N/A
Income Before Tax (EBT)	-26.17M	-39.40M	-49.50M	-29.92M	-10.17M	-18.87M	-16.16M	19K
Interest Income	223K	865K	1.39M	N/A	N/A	N/A	N/A	343K
Interest Expense	2.68M	4.06M	4.56M	3.30M	870K	950K	88K	N/A
Other Income/Expense	-3.09M	-6.31M	-8.96M	18.49M	39.81M	1.34M	177K	343K
Net Income	-26.17M	-39.40M	-49.50M	-29.92M	-9.74M	-19.28M	-16.16M	-277K
Income Tax Expense	0.00	0.00	0.00	0.00	-428K	406K	0.00	0.00
Net Profit Margin	-13086.5%	-11520.5%	-7569.4%	-6325.2%	-1347.2%	-9357.8%	N/A	N/A
EBITDA	-21.59M	-31.45M	-38.84M	-47.39M	-49.02M	-19.25M	-15.43M	348K
EBITDA Margin	-10794.0%	-9195.3%	-5938.1%	-10019.0%	-6780.5%	-9345.1%	N/A	N/A
Depreciation & Amortization	1.50M	1.65M	1.71M	1.02M	955K	963K	900K	672K
EPS Basic	-2.65	-5.67	-9.43	N/A	-3.16	-5.51	-4.69	-0.09
EPS Diluted	-2.65	-5.67	-9.43	N/A	-3.16	-5.51	-4.69	-0.09
Weighted Average Basic Shares	9.86M	6.95M	5.25M	3.26M	3.08M	3.50M	3.47M	3.12M
Weighted Average Diluted Shares	9.86M	6.95M	5.25M	3.26M	3.08M	3.50M	3.47M	3.12M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.